Annapurna Therapeutics Limited

Annapurna Therapeutics is a gene therapy company focused on discovering and developing new therapeutic products for people living with severe diseases. Annapurna’s product pipeline includes programs for alpha-1 antitrypsin (A1AT) deficiency, hereditary angioedema (HAE), the cardiomyopathy associated with Friedreich’s ataxia and severe allergy. Annapurna Therapeutics was acquired by Avalanche Biotechnologies, Inc. in 2016.

Ecolectro, Inc.

Ecolectro develops structurally robust and highly conductive polymer membranes for a range of applications, including electrolysis and fuel cell systems that not only improve performance but also dramatically decrease costs.

Embark Veterinary, Inc.

Embark is a veterinary science-focused company specializing in canine genetics. Through the use of cutting-edge genetic testing and analysis, Embark offers 21st century pet wellness advice coupled with comprehensive ancestry, morphological trait, and genetic disease information for dog owners.

CycloPure, Inc.

CycloPure is engaged in the design, development, and commercialization of a new class of highly adsorbent materials for use in the separation and removal of pollutants, VOCs, and other organic compounds from water and air. The technology was partly developed by the Helbling Research Group at The School of Civil and Environmental Engineering. CycloPure has raised $8.81M in funding to date.

Fesarius Therapeutics, Inc.

Fesarius Therapeutics is developing engineered tissue scaffold products for the skin and dermal layers. The products are based off the patent-pending microstructure-containing gel scaffold technology developed at Cornell. The acellular skin replacement will aim to benefit those with wounds resulting from burns, plastic surgery, tumor removal, and other forms of trauma. The company joined the National Institutes of Health as part of its I-Corps @ NIH Winter 2020 Program in February 2020.

Lumidyne Technologies, LLC

Lumidyne develops next-generation fluorescent probes exhibiting superior brightness and stability compared with current commercially available reagents.

Immunovent, LLC

Immunovent, LLC is focused on the commercialization of next-generation technologies for allergy diagnosis. The company is developing the Local Allergy Mucosal Brush Test (LAMB-Dx), the first quantitative allergy diagnostic that will enable physicians to accurately test for both airborne and food allergies precisely where the clinical symptoms are occurring – in the mouth and nose.

TeraPore Technologies, Inc.

TeraPore Technologies, Inc. develops membrane technologies for high-permeability, high-resolution separations including purification of biological fluids.

TaggPic, Inc.

TaggPic transforms static 2D photos into auto-tagged, geo-positioned, and intelligently connected platforms. TaggPic’s crowd-fueled computer vision technology instantly recognizes landmarks, buildings, and other objects in images without the need for GPS data or manual tagging. TaggPic was acquired by Google in 2014.

WOTN, LLC

WOTN is a risk software company that provides an independent, real-time, simulation-based risk management platform for the $1T commercial mortgage backed securities market. The patent pending technology provides risk measurements on demand for loans and bonds in the derivative structure compliant with Basel in a comprehensive portfolio management system.